A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments — Stella
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
United States
GSK Investigational Site, Grand Rapids, Michigan
GSK Investigational Site, Chapel Hill, North Carolina
GSK Investigational Site, Chattanooga, Tennessee
GSK Investigational Site, Nashville, Tennessee
Argentina
GSK Investigational Site, Ciudadela
GSK Investigational Site, San Juan Bautista
GSK Investigational Site, Viedma
Australia
GSK Investigational Site, Fitzroy, Victoria
GSK Investigational Site, Nedlands, Western Australia